A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
Abstract The current COVID-19 pandemic has heavily burdened the global public health system and may keep simmering for years. The frequent emergence of immune escape variants have spurred the search for prophylactic vaccines and therapeutic antibodies that confer broad protection against SARS-CoV-2...
Main Authors: | Zhenlin Yang, Yulu Wang, Yujia Jin, Yuanfei Zhu, Yanling Wu, Cheng Li, Yu Kong, Wenping Song, Xiaolong Tian, Wuqiang Zhan, Ailing Huang, Shanshan Zhou, Shuai Xia, Xiaoxu Tian, Chao Peng, Cuicui Chen, Yibing Shi, Gaowei Hu, Shujuan Du, Yuyan Wang, Youhua Xie, Shibo Jiang, Lu Lu, Lei Sun, Yuanlin Song, Tianlei Ying |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-11-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-021-00810-1 |
Similar Items
-
The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2
by: Xiaolong Tian, et al.
Published: (2022-12-01) -
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
by: Xiaolong Tian, et al.
Published: (2020-01-01) -
Inhalable antibodies for the treatment of COVID-19
by: Zhenlin Yang, et al.
Published: (2022-11-01) -
The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2
by: Cheng Li, et al.
Published: (2021-03-01) -
Insights into biological therapeutic strategies for COVID-19
by: Xiaolong Tian, et al.
Published: (2021-03-01)